08:00 | Registration |
| LATE-PCR |
| |
09:00 | | Keynote Presentation Analysis of Multidrug Resistant Tuberculosis using LATE-PCR with Lights-On/Lights-Off Probes, or with Lights-Off Only Probes – A New Technology Lawrence Wangh, Professor, Brandeis University, United States of America
Diagnosis of multidrug resistant tuberculosis is a major health problem spurring invention of new technologies. LATE-PCR efficiently generates single-strand amplicons for many targets that can either be analyzed in a single-tube using Lights-On/Lights-Off probes, or in parallel tubes using Lights-Off Only probes. |
|
10:00 | PCR-Perfect: a Multifaceted Reagent for Optimizing PCR Amplification and Analysis John Rice, Senior Research Scientist, Brandeis University, United States of America
PCR-Perfect is a novel non-amplifiable reagent that suppresses all forms of mis-priming, serves as a temperature-mark to reveal reaction-to-reaction variations in composition, and serves as an internal standard. |
10:30 | Coffee Break & Networking in Exhibition Hall |
11:15 | Single-tube Mutation Scanning of Epidermal Growth Factor Receptor Gene using Multiplex LATE-PCR and Lights-On/Lights-Off Probes J. Aquiles Sanchez, Senior Research Scientist, Brandeis University, United States of America
We describe a clinically-compatible, single-tube PCR method for sensitive screening of samples with mutations in EGFR exons 18-21 that determine the response of cancer patients to anti-EGFR therapies. The method generates unique fluorescent signatures that are characteristic of the amplified gene sequences. |
11:45 | Highly Divergent Gene Families are Efficiently Amplified Using Low-concentration Initiator Primers Kenneth Pierce, Senior Research Scientist, Brandeis University, United States of America
Detecting sequences of divergent bacterial or viral genes can be challenging. LATE-PCR consensus primers combined with low concentrations of initiator primers (i Primers) enable consistent amplification of such targets, including the CTX-M antibiotic resistance gene family. |
12:15 | Technology Spotlight: Finding Your Way Through the Bioinformatics Maze Sarah Lynagh, COO, Fios Genomics Ltd
Practical approaches to getting to the most from ‘omic data sets and using the emerging technologies in a practical way. |
12:30 | Lunch & Networking in Exhibition Hall |
13:30 | Poster Viewing Session |
14:15 | Sepsis, MRSA, VAP: Molecular Pathogen and Antibiotic Resistance Detection in a Single Tube Multiplex LATE-PCR Assay Arthur Reis, Senior Research Scientist, Brandeis University, United States of America
LATE-PCR single tube multiplex assays for the detection of Sepsis, MRSA and VAP infections including antibiotic resistance genes will be described from assay design to testing on clinical samples. |
14:45 | Analysis of Heteroplasmy Among Mitochondrial Genomes at the Single Molecule Level using LATE-PCR and Allied Technologies Adam Osborne, Researcher, Brandeis University, United Kingdom
A LATE-PCR Lights-On/Lights-Off probe assay was developed to look for mutations in the mitochondrial genome. Exposure of both HepG2 and CCD-1112Sk cells to 3'-Azido-3'-deoxythymidine (AZT) caused a significant increase in mutations in regions of the HV2 and ND1 genes. |
15:15 | Coffee Break & Networking in Exhibition Hall |
| qPCR in Diagnostics |
| |
16:00 | DiSSeCT Technology Provides Mutation Enrichment Prior to PCR or COLD-PCR and Enables Detection of Traces of Rare Mutations in Cancer Samples Mike Makrigiorgos, Professor, Dana-Farber Cancer Institute/Harvard Medical School, United States of America
Multiplex detection of low-level mutant alleles in the presence of wild-type DNA is useful for several fields of medicine including cancer, pre-natal diagnosis and infectious diseases. We present DiSSeCT, a new technology that enables detection of traces of mutations in cancer and circulating DNA when combined with PCR. |
16:30 | Development and Validation of a High Sensitivity SNaPshot Assay for Mutation Profiling of Non-Small Cell Lung Cancer (NSCLC) Patients Preveen Ramamoorthy, Assistant Professor/Director, National Jewish Health, United States of America
Non-small cell lung carcinoma represents the primary cause of cancer-related death in both men and women in the United States. Molecular profiling of tumor mutations is the key to implementation of a personalized therapeutic approach for NSCLC patients. Our laboratory has developed a molecular diagnostic test for NSCLC based on SNaPshot methodology for resected NSCLC tumor specimens. Our challenge was to extend the SNaPshot assay to much smaller specimens, such as transbronchial biopsy samples as well as core-needle biopsies. |
17:45 | Round Table Discussions in the Exhibition Hall |
19:00 | End of Day One |